G. Zeren, İ. Avcı, M. Sungur, B. Şimşek, Aylin Sungur, F. Can, M. F. Yılmaz, Ufuk Gürkan, S. Kalkan, A. Karagöz, I. Tanboğa, C. Karabay
{"title":"Effects of RAAS blocker use on AKI in elderly hypertensive STEMI patients with propensity score weighed method","authors":"G. Zeren, İ. Avcı, M. Sungur, B. Şimşek, Aylin Sungur, F. Can, M. F. Yılmaz, Ufuk Gürkan, S. Kalkan, A. Karagöz, I. Tanboğa, C. Karabay","doi":"10.1080/10641963.2022.2071922","DOIUrl":null,"url":null,"abstract":"ABSTRACT Studies reported conflicting results on the effect of renin-angiotensin-aldosterone system (RAAS) blocker use on acute kidney injury (AKI) in patients undergoing elective coronary angiography but association in elderly patients with ST-elevation myocardial infarction (STEMI) is not known. Also, there are limited data on the effect of inflammatory markers on AKI. We aimed to investigate the effects of RAAS blocker pretreatment and inflammatory markers on AKI in this population. A total of 471 patients were compared according to presence of RAAS blocker pretreatment at admission. Conventional and inverse probability weighed conditional logistic regression were used to determine independent predictors of AKI. Mean age of the study group was 75.4 ± 7.1 years and 29.1% of the patients were female. AKI was observed in 17.2% of the study population. Weighted conditional multivariable logistic regression analysis revealed that AKI was associated with baseline creatinine levels and C-reactive protein/albumin ratio (CAR) (OR 2.08, 95% CI = 1.13–3.82, p = .02 and OR 1.19, 95% CI = 1.01–1.41, p = .04, respectively). No significant association was found between RAAS blocker pretreatment and AKI. CAR and elevated baseline creatinine levels were independent predictors of AKI in this patient group.","PeriodicalId":10333,"journal":{"name":"Clinical and Experimental Hypertension","volume":"386 1","pages":"487 - 494"},"PeriodicalIF":1.5000,"publicationDate":"2022-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Hypertension","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10641963.2022.2071922","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0
Abstract
ABSTRACT Studies reported conflicting results on the effect of renin-angiotensin-aldosterone system (RAAS) blocker use on acute kidney injury (AKI) in patients undergoing elective coronary angiography but association in elderly patients with ST-elevation myocardial infarction (STEMI) is not known. Also, there are limited data on the effect of inflammatory markers on AKI. We aimed to investigate the effects of RAAS blocker pretreatment and inflammatory markers on AKI in this population. A total of 471 patients were compared according to presence of RAAS blocker pretreatment at admission. Conventional and inverse probability weighed conditional logistic regression were used to determine independent predictors of AKI. Mean age of the study group was 75.4 ± 7.1 years and 29.1% of the patients were female. AKI was observed in 17.2% of the study population. Weighted conditional multivariable logistic regression analysis revealed that AKI was associated with baseline creatinine levels and C-reactive protein/albumin ratio (CAR) (OR 2.08, 95% CI = 1.13–3.82, p = .02 and OR 1.19, 95% CI = 1.01–1.41, p = .04, respectively). No significant association was found between RAAS blocker pretreatment and AKI. CAR and elevated baseline creatinine levels were independent predictors of AKI in this patient group.
研究报告了肾素-血管紧张素-醛固酮系统(RAAS)阻滞剂对选择性冠状动脉造影患者急性肾损伤(AKI)的影响的相互矛盾的结果,但与老年st段抬高型心肌梗死(STEMI)患者的关联尚不清楚。此外,关于炎症标志物对AKI的影响的数据有限。我们的目的是研究RAAS阻断剂预处理和炎症标志物对该人群AKI的影响。471例患者根据入院时是否存在RAAS阻滞剂进行比较。采用常规和逆概率加权条件logistic回归确定AKI的独立预测因子。研究组平均年龄75.4±7.1岁,女性占29.1%。在17.2%的研究人群中观察到AKI。加权条件多变量logistic回归分析显示AKI与基线肌酐水平和c反应蛋白/白蛋白比(CAR)相关(OR分别为2.08,95% CI = 1.13-3.82, p = 0.02和OR为1.19,95% CI = 1.01-1.41, p = 0.04)。RAAS阻滞剂预处理与AKI之间无显著相关性。CAR和基线肌酐水平升高是该患者组AKI的独立预测因子。
期刊介绍:
Clinical and Experimental Hypertension is a reputable journal that has converted to a full Open Access format starting from Volume 45 in 2023. While previous volumes are still accessible through a Pay to Read model, the journal now provides free and open access to its content. It serves as an international platform for the exchange of up-to-date scientific and clinical information concerning both human and animal hypertension. The journal publishes a wide range of articles, including full research papers, solicited and unsolicited reviews, and commentaries. Through these publications, the journal aims to enhance current understanding and support the timely detection, management, control, and prevention of hypertension-related conditions.
One notable aspect of Clinical and Experimental Hypertension is its coverage of special issues that focus on the proceedings of symposia dedicated to hypertension research. This feature allows researchers and clinicians to delve deeper into the latest advancements in this field.
The journal is abstracted and indexed in several renowned databases, including Pharmacoeconomics and Outcomes News (Online), Reactions Weekly (Online), CABI, EBSCOhost, Elsevier BV, International Atomic Energy Agency, and the National Library of Medicine, among others. These affiliations ensure that the journal's content receives broad visibility and facilitates its discoverability by professionals and researchers in related disciplines.